RE:RE:RE:RE:I agree that financials will do nothing for the share priceThe science and medicine worlds say that covid is here to stay, and that we need to learn to live with it; therefore, covid testing is here to stay, I would assume. A time will come when the investment world catches up with what science already knows, and starts giving value to covid plays. That said, Datametrex is NOT a "covid play". They just happened to be smart enough to see an opportunity to help and earn money, at a time when businesses all around them were flailing to survive. This winfall is just that: A load of cash, being dropped on their head. But has it deterrered them in any way? Not one bit. And as myself and others here keep saying, it's actually funding and expediting their goals.
So, what's keeping the stock price down? Probably it's partly the impatient people who don't do thorough enough DD and can't quite see beyond the covid money, and can't quite grasp that DM is an AI company first, and all other venues (including covid) second. Early in the Covid-19 days (mid 2020 I think), a portfolio manager making a guest appearance on BNN answered a call-in question about Datametrex AI. The caller did a good job of outlining DM and SMART. The portfolio manager hadn't heard of DM, but replied (extremely rudely) on the recent bump up in their chart, and basically referred to them as a covid play that they would not touch, essentially belittling them for their previously low stock price. My feeling is that he and similar-minded naysayers who can't see this tightly wound gem for what it actually is are about to get schooled, not just on DM's increasing AI value, but it's continuing covid test kit value too.